DxS Plans PMA For Companion Test To Amgen Colorectal Cancer Drug

Personalized medicine company DxS is preparing a PMA application for a companion diagnostic to Amgen's colorectal cancer drug Vectibix, supported by clinical utility data from a recent Amgen-sponsored clinical trial, according to DxS CEO Stephen Little

More from Archive

More from Medtech Insight